Solid cancer, antiphospholipid antibodies, and venous thromboembolism

Autoimmunity Reviews

Volumn 10, Issue 4, 2011, Pages 222-227

  Font, Carme ^a   Vidal, Laura ^a   Espinosa, Gerard ^a   Tàssies, Dolors ^a   Monteagudo, Joan ^a   Farrús, Blanca ^a   Visa, Laura ^a   Cervera, Ricard ^a   Gascon, Pere ^a   Reverter, Joan C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Autoimmunity; Cancer; Thrombophilia; Venous thromboembolism

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PATHOGENESIS; PREVALENCE; REVIEW; SOLID TUMOR; VENOUS THROMBOEMBOLISM;

AGED; ANTIBODIES, ANTIPHOSPHOLIPID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 79951850402     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.10.006     Document Type: Review

References (37)

1. Lee A.Y.Y., Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107:17-21.
2. Prandoni P., Falanga A., Piccioli P. Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401-410.
3. Sallah S., Husain A., Sigounas V., Wan J., Turturro F., Sigounas G., et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004, 10:7238-7243.
4. Streiff M.B. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009, 27:4889-4894.
5. Ay C., Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res 2010, 125:S12-S15.
6. Kiss E., Kovacs L., Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010, 9:195-199.
7. Zampieri S., Valente M., Adami N., Biral D., Ghirardello A., Rampudda M.E., et al. Polymyositis, dermatomyositis and malignancy: a further intringuing link. Autoimmun Rev 2010, 9:449-453.
8. Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett 2009, 281:8-23.
9. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009, 8:410-414.
10. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune diseases. Autoimmun Rev 2010, 9:A259-A266.
11. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
12. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:299-304.
13. Zinger H., Sherer Y., Goddard G., Berkun Y., Barzilai O., Agmon-Levin N., et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus 2009, 18:1149-1153.
14. Sène D., Piette J.C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008, 7:272-277.
15. Gómez-Puerta J.A., Cervera R., Espinosa G., Aguiló S., Bucciarelli S., Ramos-Casals M., et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006, 35:322-332.
16. Schved J.F., Dupuy-Fons C., Biron C., Quére I., Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994, 24:175-182.
17. Tincani A., Taraborelli M., Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010, 9:200-202.
18. Yoon K.H., Wong A., Shakespeare T., Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003, 12:112-116.
19. Zuckerman E., Toubi E., Dov Golan T., Rosenvald-Zuckerman T., Sabo E., Shmuel Z. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995, 72:447-451.
20. Armas J.B., Dantas J., Mendonça D., Farto R., Ribeiro M., Herrero-Beaumont G., et al. Anticardiolipin and antinuclear antibodies in cancer patients-a case control study. Clin Exp Rheumatol 2000, 18:227-232.
21. Bazzan M., Montaruli B., Vaccarino A., Fornari G., Saitta M., Prandoni P. Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study. Intern Emerg Med 2009, 6:491-495.
22. Ozgürogglu M., Arun B., Erzin Y., Demir G., Demirelli F., Mandel N., et al. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost 1999, 5:181-184.
23. Reinstein E., Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allerg Immunol 2007, 32:184-187.
24. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
25. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors/UICC 4th ed (corrected 2nd ed) 1999, Springer-Verlag, Berlin, Germany.
26. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
27. Büller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:401-428.
28. Kearon C., Khan S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:454-545.
29. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
30. Turna H., Ozguroglu M., Bolayirli M., Orhanoglu T., Balci H. Is there any effect of tumor burden on hemostatic parameters in cancer patients? A case-control study of hemostatic abnormalities and anticardiolipin antibodies in solid tumors. Clin Appl Thromb Hemost 2009, 15:454-457.
31. De Meis E., Monteiro R.Q., Levy R.A. Lung adenocarcinoma and antiphospholipid antibodies. Autoimmu Rev 2009, 8:529-532.
32. Bloom J.W., Osanto S., Rosendaal R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004, 2:1760-1765.
33. Galli M. Clinical utility of laboratory test used to identify antiphospholipid antibodies and to diagnose antiphospholipid syndrome. Semin Thromb Haemost 2008, 34:329-334.
34. Favaloro E.J., Wong R.C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Haemost 2008, 34:389-410.
35. Bombeli T., Karsan A., Tait J.F., Harlan J.M. Apoptotic vascular endotelial cells become procoagulant. Blood 1997, 89:2429-2442.
36. Sugimura M., Donato R., Kakkar V.V., Scully M.F. Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul Fibrinolysis 1994, 5:365-373.
37. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002, 62:6132-6140.